Can Contrast-Enhanced Spectral Mammography (CESM) Reduce Benign Breast Biopsy?

Objectives. To evaluate the potential of contrast-enhanced spectral mammography (CESM) in reducing benign breast biopsy rate, thereby improving resource utilization. To explore its potential as a value-adding modality in the management of BI-RADS 4/5 lesions. Materials and Methods. This was a prospe...

Full description

Saved in:
Bibliographic Details
Published in:The breast journal 2022-03, Vol.2022, p.1-9
Main Authors: Liew, Amanda Ling Fung, Lim, Hollie Mei Yeen, Fok, Elizabeth Chun Mei, Loke, Siu Cheng, Tan, Ern Yu, Chong, Bee Kiang, Lee, Yeong Shyan, Chan, Patrick Mun Yew, Chotai, Niketa
Format: Article
Language:English
Subjects:
Benign
Biopsy
Breast
Breast cancer
Chi-square test
Digital imaging
Evaluation
Histology
Histopathology
Image enhancement
Iodine
Lesions
Magnetic resonance imaging
Mammography
Pathology
Patients
Resource allocation
Resource utilization
Ultrasonic imaging
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To evaluate the potential of contrast-enhanced spectral mammography (CESM) in reducing benign breast biopsy rate, thereby improving resource utilization. To explore its potential as a value-adding modality in the management of BI-RADS 4/5 lesions. Materials and Methods. This was a prospective study conducted between July 2016 and September 2018. Patients with BI-RADS 4/5 lesions detected on conventional imaging (mammogram, digital breast tomosynthesis, and ultrasound) were enrolled for adjunct CESM. Histopathologic correlation was done for all lesions. Additional suspicious lesions detected on CESM were all identified on second-look ultrasound and subsequently biopsied. Images were evaluated independently by two radiologists trained in breast imaging using BI-RADS classification. Presence of enhancement on CESM, BI-RADS score, and histopathology of each lesion were analyzed and tested with the chi-square/fisher-exact test for statistical significance. Results. The study included 105 lesions in 63 participants—1 man and 62 women, an average age of 53.7 ± 10.8 years. On CESM, 22 (20.9%) of the lesions did not show enhancement. All 22 lesions had been classified as BI-RADS 4A and were subsequently proven to be benign. Of the remaining 83 enhancing lesions, 54 (65.1%) were malignant and 29 (34.9%) were benign (p
ISSN:1075-122X
1524-4741
DOI:10.1155/2022/7087408